Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists

Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6. doi: 10.1016/s0960-894x(00)00169-4.

Abstract

A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha1a adrenergic receptor (alpha1a-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha1a-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha1-adrenergic antagonists.

MeSH terms

  • Adrenergic Antagonists / chemistry*
  • Adrenergic Antagonists / metabolism
  • Adrenergic Antagonists / pharmacology*
  • Adrenergic alpha-1 Receptor Antagonists*
  • Animals
  • Biochemistry / methods
  • COS Cells / metabolism
  • Cell Membrane / metabolism
  • Drug Evaluation, Preclinical / methods
  • Humans
  • In Vitro Techniques
  • Male
  • Muscle Contraction / drug effects
  • Muscle, Smooth / drug effects
  • Piperazine
  • Piperazines / chemistry*
  • Piperazines / metabolism
  • Piperazines / pharmacology*
  • Piperidines / chemistry*
  • Piperidines / metabolism
  • Piperidines / pharmacology*
  • Prostate / drug effects
  • Rats
  • Receptors, Adrenergic, alpha-1 / genetics
  • Receptors, Adrenergic, alpha-1 / metabolism
  • Recombinant Proteins / drug effects
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Structure-Activity Relationship

Substances

  • 1-(2-isopropoxyphenyl)-4-((2-oxopiperidin-1-yl)acetamido)propylpiperazine
  • ADRA1A protein, human
  • ADRA1B protein, human
  • ADRA1D protein, human
  • Adrenergic Antagonists
  • Adrenergic alpha-1 Receptor Antagonists
  • Piperazines
  • Piperidines
  • Receptors, Adrenergic, alpha-1
  • Recombinant Proteins
  • Piperazine